← Eichor
Study identifier: NCT05331170 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Viral Mucosal Reprogramming

Condition: Asthma · Allergic Rhinitis · Cat Allergy  ·  Sponsor: The University of Texas Medical Branch, Galveston

PhasePhase 2
Planned participants75
Who can joinAll sexes, 18 Years to 60 Years
Healthy volunteersYes

About this study

This is a mechanistic, controlled, open-label, single-site study to evaluate the effects of RG-RV16 inoculation on airway mucosal gene expression and airway remodeling in 25 healthy controls (HC), in 25 allergic rhinitis subjects (AR) with cat dander allergy, and in 25 allergic asthmatic subjects (AA) with cat dander allergy. Three groups (HC, AR, and AA) will undergo screening to establish clinical history, will undergo pulmonary function testing (spirometry), and will have blood drawn for clinical characterization (IgE, , ImmunoCAP, CBC and differential), and for assessing the presence of existing neutralizing antibody against RV16. Only those who meet criteria will be permitted to continue into the interventional and run-out phases of the study.

This description comes directly from the study's public registry record.

Talk to the study team

Lisa Sweeney, RN  ·  409-747-5871  ·  lanemeth@utmb.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of Texas Medical BranchGalveston, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05331170